Press release, Helsinki, 11 August, 2017 there is a 9.00
Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or the “company“), a medical device company that developed and markets a ground-breaking system to navigate a non-invasive brain stimulation for therapeutic applications and diagnostic applications. The company reports first half-year to 30 June 2017 Wednesday 16 August 2017, about 9 a.m. Finnish time.
A conference call targeted to the media, investors and analysts, organised on Wednesday, 16 August 2017, at 16.00 Finnish time. Chairman of the board and managing director Martin Jamieson and cfo Mikko Karvinen presents the financial results and the profit after which participants are given the opportunity to ask questions.
Call into the conference call:
Finland: +358 (0) 800 914672
Sweden: +46 (0) 20 089 6377
Uk: +44 (0) 20 3003 2666
The united states: + 1 866 966 5335
International: +44 (0) 20 3003 2666
The call password: Nexstim
The report for the fiscal year ending 31 december 2017 will be published on or around 28 February 2018.
Martin Jamieson, chairman of the board and ceo
Additional information is available on the website
or per telephone:
Nexstim +44 771 516 39 42
Martin Jamieson, chairman of the board and ceo email@example.com
UB Securities Oy (Certified Adviser) +358 (0)9 2538 02 46
Citigate Dewe Rogerson +44 (0)207 2822949
David Dible/Isabelle Andrews/Shabnam Bashir firstname.lastname@example.org
About Nexstim Plc
Nexstim is a medical device company that developed and markets a ground-breaking system to navigate a non-invasive brain stimulation for therapeutic applications (NBT®system) and diagnostic applications (NBS-system). Nexstims NBS system is the first and only FDA-approved and CE-marked system to navigate transcranial magnetic stimulation (navigated Transcranial Magnetic Stimulation, nTMS) for mapping of the areas of motor skills and speech in the brain before a surgical procedure.
On the same technology platform the company has developed a system to navigate hjärnterapi (Navigated Brain Therapy, NBT®), which has received CE marking in Europe for the treatment of stroke, severe depression and chronic neuropathic pain.
Nexstim recently applied on the 510(k) approval with the FDA for the use of the NBT®system for the treatment of major depressive disorder (MDD). Nexstim looking forward to the launch of the NBT®system for this important indication in the beginning of 2018. The NBT®system is currently undergoing additional Phase III trials (E-FIT) with 60 patients. Nexstim expects the trial ends the second quarter of 2018 and that the company then can request for authorization from the FDA. With the approval from the FDA would Nexstim able to begin marketing and selling the NBT®system for the treatment of stroke in the united states.
Nexstims shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. More information is available at www.nexstim.com.
Publishing of Nexstim Plc’s interim report for H1 2017
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nexstim Oyj via Globenewswire